<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03701399</url>
  </required_header>
  <id_info>
    <org_study_id>BHV4157-206</org_study_id>
    <nct_id>NCT03701399</nct_id>
  </id_info>
  <brief_title>Troriluzole in Adult Subjects With Spinocerebellar Ataxia</brief_title>
  <official_title>A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Subjects With Spinocerebellar Ataxia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biohaven Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biohaven Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of Troriluzole (200mg once daily) versus
      placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the total score of the Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA) after 48 weeks of treatment.</measure>
    <time_frame>Baseline to week 48</time_frame>
    <description>An increase in the total score indicates a worsening of symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Change from baseline in Patient Impression of Function and Activities of Daily Living Scale (PIFAS) score at Randomization Phase Week 48</measure>
    <time_frame>Baseline to week 48</time_frame>
    <description>An increase in the total score indicates a worsening of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Activities of Daily Living Scale from the Friedreich's Ataxia Rating Scale (FARS-ADL) at Randomization Week 48.</measure>
    <time_frame>Baseline to week 48</time_frame>
    <description>An increase in the total score indicates a worsening of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Functional Staging for Ataxia from the Friedreich's Ataxia Rating Scale (FARS-FUNC) at Randomization Phase Week 48</measure>
    <time_frame>Baseline to week 48</time_frame>
    <description>An increase in the total score indicates a worsening of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4. Frequency of subjects with the following adverse events (AEs) identified from case report forms: AEs (by severity; by relationship to study drug; overall); SAEs; and AEs leading to treatment discontinuation.</measure>
    <time_frame>Baseline to week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Spinocerebellar Ataxias</condition>
  <condition>Spinocerebellar Ataxia Type 1</condition>
  <condition>Spinocerebellar Ataxia Type 2</condition>
  <condition>Spinocerebellar Ataxia Type 3</condition>
  <condition>Spinocerebellar Ataxia Type 6</condition>
  <condition>Spinocerebellar Ataxia Type 7</condition>
  <condition>Spinocerebellar Ataxia Type 8</condition>
  <condition>Spinocerebellar Ataxia Type 10</condition>
  <arm_group>
    <arm_group_label>Arm 1: BHV-4157</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Troriluzole 200mg PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 200mg PO</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>troriluzole</intervention_name>
    <description>200 mg PO</description>
    <arm_group_label>Arm 1: BHV-4157</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>200 mg PO</description>
    <arm_group_label>Arm 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with a known or suspected diagnosis of the following specific hereditary
             ataxias: SCA1, SCA2, SCA3, SCA6, SCA7, SCA8 and SCA10; currently only enrolling SCA 1,
             SCA2, SCA3, SCA7, and SCA10 (the cap has been met for SCA6 and SCA8 (on May 31,
             2019));

               1. A subject should have a confirmed genotypic diagnosis from a CLIA certified lab
                  (can produce test results); or,

               2. A subject has a family member that has a confirmed genotypic diagnosis from a
                  CLIA certified lab (can produce test results) and must be willing to undergo
                  genetic testing to confirm underlying SCA diagnosis; or,

               3. A subject has a confirmed genotypic diagnosis from a lab that is not CLIA
                  certified and must be willing to undergo genetic testing to confirm underlying
                  SCA diagnosis; or,

               4. A subject has clinical evidence that supports diagnosis of one of the
                  aforementioned SCA genotypes but does not have producible test results from a
                  CLIA certified lab from either a family member or for his or herself and the
                  subject must be willing to undergo such testing to confirm the SCA diagnosis (in
                  this case, site must wait for results of genotypic testing prior to
                  randomization)

          2. Ability to ambulate 8 meters without human assistance (canes and other devices
             allowed)

          3. Screening f-SARA total score ≥3;

          4. Score of ≥1 on gait subsection of the f-SARA

          5. Determined by the investigator to be medically stable at Baseline/randomization as
             assessed by medical history, physical examination, laboratory test results, and
             electrocardiogram testing.

        Exclusion Criteria:

          1. A ≥ 2-point difference on the Modified Functional SARA score between screening and
             baseline

          2. MMSE score &lt;24

          3. Any medical condition other than one of the hereditary ataxias specified in the
             inclusion criteria that could predominantly explain or contribute significantly to the
             subjects' symptoms of ataxia.

          4. A prominent spasticity or dystonia that, in the opinion of the investigator, will
             compromise the ability of the SARA instrument to assess underlying ataxia severity.

          5. A score of 4 on any individual item (Items 1-4) of the f-SARA

          6. Subjects should be excluded at screening or baseline if medical conditions have arisen
             or there is a change in disease status that could confound the ability of the SARA to
             accurately reflect changes in ataxia severity.

          7. Active liver disease or a history of hepatic intolerance to medications that in the
             investigator's judgment, is medically significant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elyse Stock, MD</last_name>
    <phone>203-404-0410</phone>
    <email>clinicaltrials@biohavenpharma.com/</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giulia Andrews</last_name>
      <email>Giulia.Andrews@dignityhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNS Trials</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Cabral</last_name>
      <phone>562-304-1742</phone>
      <email>annecabral@cnstrial.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Fisher</last_name>
      <phone>310-206-8153</phone>
      <email>adfisher@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Tallakson</last_name>
      <phone>415-502-7640</phone>
      <email>joseph.tallakson@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Haakonsen</last_name>
      <phone>303-724-6351</phone>
      <email>NICOLA.HAAKONSEN@UCDENVER.EDU</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida Health</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Gullett</last_name>
      <phone>352-273-5550</phone>
      <email>Stephen.Gullett@neurology.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Stongosky, MD</last_name>
      <phone>904-953-7229</phone>
      <email>Strongosky.Audrey2@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Freeman</last_name>
      <phone>813-974-5909</phone>
      <email>mfreema4@health.usf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole Seeley</last_name>
      <phone>404-727-8748</phone>
      <email>Carole.seeley@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ZsaZsa Brown</last_name>
      <phone>312-503-4121</phone>
      <email>zsazsa.brown@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Jimenez</last_name>
      <phone>773-702-1848</phone>
      <email>cindyj@uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Neurology, Ltd.</name>
      <address>
        <city>Rolling Meadows</city>
        <state>Illinois</state>
        <zip>60008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Frizelis</last_name>
      <phone>847-839-4395</phone>
      <email>kfrizelis@northwestneuro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Medicine</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Johnson</last_name>
      <phone>410-616-2816</phone>
      <email>vjohns23@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colin Villarin</last_name>
      <phone>617-726-4942</phone>
      <email>Cvillarin@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilanda Gabriel</last_name>
      <phone>617-975-7637</phone>
      <email>wgabriel@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tasha Kaiser</last_name>
      <email>kaisert@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia Amokrane</last_name>
      <phone>212-305-7963</phone>
      <email>na2855@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Movement Disorders Clinic</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen White-Tong</last_name>
      <phone>919-668-2905</phone>
      <email>karen.white@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcela Pavon</last_name>
      <phone>215-829-7725</phone>
      <email>Marcela.Pavon@uphs.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Titilayo Olubajo</last_name>
      <phone>713-363-9803</phone>
      <email>tolubajo@houstonmethodist.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Health Services</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Johnson</last_name>
      <phone>206-320-7115</phone>
      <email>Laura.Johnson3@swedish.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 5, 2018</study_first_submitted>
  <study_first_submitted_qc>October 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2018</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ataxia, SCA, Spinocerebellar Ataxia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Spinocerebellar Ataxias</mesh_term>
    <mesh_term>Spinocerebellar Degenerations</mesh_term>
    <mesh_term>Machado-Joseph Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

